Article
SR One breaks off from GlaxoSmithKline, banks $500M fund
Rating:
0.0
Views:
50
Likes:
1
Library:
1
SR One has backed biotech companies for decades as GlaxoSmithKline's venture arm. Now, the firm is striking out on its own, having spun out from the British conglomerate and raised a whopping $500 million fund. The fund, SR One's first, will back “elite” biotechs on both sides of the Atlantic, working on new medicines to address treatment gaps.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value